Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Network meta-analysis of success rate and safety in antibiotic treatments of bronchitis

Authors Wang J, Xu H, Liu P, Li M

Received 12 April 2017

Accepted for publication 5 July 2017

Published 9 August 2017 Volume 2017:12 Pages 2391—2405

DOI https://doi.org/10.2147/COPD.S139521

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Jinghua Wang,1 Haiyang Xu,2 Pan Liu,3 Mingxian Li4

1Pediatric of Rheumatology, Immunology and Allergy, The First Hospital of Jilin University, Changchun, 2Department of Anesthesiology, The First Hospital of Jilin University, Changchun, 3Department of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 4Department of Respiratory, The First Hospital of Jilin University, Changchun, China

Abstract: The purpose of this study was to compare the relative efficacy and safety of different antibiotic drugs and recommend superior regimens in the treatment of bronchitis. With respect to the antibiotic comparisons against quinolones in terms of intention-to-treat patients, we concluded that quinolones had advantages over placebo, β-lactams, sulfonamides, and double β-lactams. Concerning treatment methods for clinically evaluable patients, quinolones demonstrated better performance than β-lactams and sulfonamides. The secondary effects of macrolides, quinolones, and double β-lactams were significantly more adverse than β-lactams with odds ratios (ORs) of 1.5 (95% credible interval [CrI] =1.1–2.0), 1.7 (95% CrI =1.2–2.3), and 2.7 (95% CrI =1.8–4.1), respectively. Significant differences in the prevalence of diarrhea as a secondary effect were only identified among the comparisons of double β-lactams against β-lactams and macrolides (OR =5.0, 95% CrI =2.1–12.0; OR =3.0, 95% CrI =1.7–5.4, respectively). Quinolones can be recommended as the superior treatment for bronchitis, in accordance with our cluster analysis with surface under the cumulative ranking curve. The primary outcomes of network meta-analysis indicated that quinolones showed the best performance among the 8 treatments studied, although β-lactams showed the lowest risk of adverse side effects. Quinolones are recommended as the primary treatment option for bronchitis patients, having taking into account the success rates and safety profiles of the eight drugs studied here.

Keywords: bronchitis, antibiotic treatments, success rate, safety, network meta-analysis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]